Upgrade to SI Premium - Free Trial

Incyte (INCY) Reiterated at Buy by Truist, Dip is a Buying Opportunity, Opzelura Launch is Key Highlight

February 8, 2022 1:31 PM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), following the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles